Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib
Authors
Discussion
Loading...
Member takes
Overview
Post-hoc analysis shows pre-HCT MRD levels vary by time from diagnosis and FLT3 inhibition in AML patients, suggesting clinical implications for gilteritinib use post-HCT.
Key Points
- To assess the impact of the time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use on measurable residual disease levels before transplant.
- Conducted post-hoc analysis of data from a global phase 3 study (BMT CTN 1506)
- Analyzed days from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use
- Evaluated FLT3-ITD MRD levels pre-HCT using a high-sensitivity assay.
- Patients transplanted within 120 days from diagnosis had significantly higher pre-HCT MRD levels.
- FLT3 inhibitor use pre-HCT correlated with lower MRD levels before transplant.
- Differences in local practice patterns affected regional outcomes and post-HCT gilteritinib benefits.
Cite This Study
Soiffer et al. (2025) studied this question.